Empower Advisory Group LLC reduced its stake in CVS Health by 66.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,490 shares of the pharmacy operator's stock after selling 13,026 shares during the quarter. Empower Advisory Group LLC's holdings in CVS Health were worth $440,000 as of its most recent SEC filing. Other hedge funds also recently made changes to their positions in the company. Dodge &amp; Cox raised its holdings in shares of CVS Health by 11.2% during the 4th quarter. Dodge &amp; Cox now owns 70,105,899 shares of the pharmacy operator's stock worth $3,147,054,000 after buying an additional 7,075,209 shares in the last quarter. Capital World Investors boosted its stake in shares of CVS Health by 26.6% in the 4th quarter. Capital World Investors now owns 61,039,777 shares of the pharmacy operator's stock valued at $2,739,927,000 after purchasing an additional 12,819,148 shares in the last quarter. Capital International Investors grew its holdings in shares of CVS Health by 4.8% during the 4th quarter. Capital International Investors now owns 26,666,401 shares of the pharmacy operator's stock valued at $1,196,989,000 after purchasing an additional 1,212,126 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in CVS Health by 14.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 13,366,403 shares of the pharmacy operator's stock worth $600,019,000 after purchasing an additional 1,660,321 shares in the last quarter. Finally, Northern Trust Corp lifted its stake in CVS Health by 8.0% in the 4th quarter. Northern Trust Corp now owns 12,491,956 shares of the pharmacy operator's stock valued at $560,764,000 after purchasing an additional 928,833 shares during the last quarter. 80.66% of the stock is owned by institutional investors. In other CVS Health news, Director bought 1,570 shares of the stock in a transaction that occurred on Thursday, June 5th. The shares were bought at an average price of $63.70 per share, for a total transaction of $100,009.00. Following the acquisition, the director directly owned 12,007 shares of the company's stock, valued at approximately $764,845.90. The trade was a 15.04% increase in their position. The acquisition was disclosed in a document filed with the Securities &amp; Exchange Commission. 1.22% of the stock is owned by corporate insiders. CVS Health Stock Up 3.0% traded up $1.91 during midday trading on Friday, hitting $65.49. The company had a trading volume of 6,458,438 shares, compared to its average volume of 9,248,730. The stock's 50 day moving average price is $64.68 and its 200 day moving average price is $64.31. CVS Health Corporation has a 52 week low of $43.56 and a 52 week high of $72.51. The company has a market capitalization of $83.06 billion, a price-to-earnings ratio of 18.29, a PEG ratio of 0.72 and a beta of 0.58. The company has a quick ratio of 0.62, a current ratio of 0.80 and a debt-to-equity ratio of 0.74. CVS Health ( - ) last issued its earnings results on Thursday, July 31st. The pharmacy operator reported $1.81 EPS for the quarter, beating analysts' consensus estimates of $1.46 by $0.35. CVS Health had a return on equity of 10.51% and a net margin of 1.17%. The business had revenue of $98.92 billion during the quarter, compared to analyst estimates of $94.87 billion. During the same period in the previous year, the company posted $1.83 EPS. The firm's revenue was up 8.4% compared to the same quarter last year. On average, research analysts anticipate that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year. CVS Health Announces Dividend The firm also recently disclosed a quarterly dividend, which was paid on Friday, August 1st. Stockholders of record on Tuesday, July 22nd were issued a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.1%. The ex-dividend date was Tuesday, July 22nd. CVS Health's dividend payout ratio (DPR) is currently 74.30%. Analyst Ratings Changes Several research analysts have recently issued reports on the stock. Robert W. Baird upped their price target on shares of CVS Health from $51.00 to $71.00 and gave the stock a \"neutral\" rating in a report on Tuesday, April 15th. Royal Bank Of Canada upped their price target on shares of CVS Health from $74.00 to $81.00 and gave the stock an \"outperform\" rating in a report on Monday, May 5th. Morgan Stanley upped their price target on shares of CVS Health from $80.00 to $82.00 and gave the stock an \"overweight\" rating in a report on Friday, August 1st. upgraded shares of CVS Health from a \"hold\" rating to a \"buy\" rating in a report on Friday, May 9th. Finally, Bernstein Bank lowered their price target on shares of CVS Health from $78.00 to $72.00 and set a \"market perform\" rating for the company in a report on Wednesday, July 16th. Three analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of \"Moderate Buy\" and an average price target of $75.11. About CVS Health CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy &amp; Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.

Empower Advisory Group LLC Reduces Stake in CVS Health Corporation (NYSE:CVS)

Empower Advisory Group LLC reduced its stake in CVS Health by 66.7% in the first quarter, selling 13,026 shares and holding 6,490 shares worth $440,000 as of the latest SEC filing. Other hedge funds such as Dodge & Cox, Capital World Investors, Capital International Investors, Price T Rowe Associates Inc. MD, and Northern Trust Corp also adjusted their positions in CVS Health during the fourth quarter. Institutional investors own 80.66% of the company's shares. A director purchased 1,570 shares at $63.70 per share, increasing their position by 15.04% to 12,007 shares valued at $764,845.90. CVS Health reported strong quarterly earnings of $1.81 EPS, beating estimates, with $98.92 billion in revenue and an 8.4% year-over-year growth. The company announced a quarterly dividend of $0.665 per share, resulting in an annualized dividend of $2.66 and a 4.1% yield. Analysts have revised price targets upward, with Morgan Stanley, Royal Bank of Canada, and Robert W. Baird increasing their targets, while Bernstein Bank lowered its target. The company has a market cap of $83.06 billion, a P/E ratio of 18.29, and a dividend payout ratio of 74.30%.